SEAM-RA trial Abst#0939 Combo TNF/MTX Rx -> ETN monoRx superior to MTX monoRx in sustaining remisson, simliar to staying on combo Rx. #ACR20 @RheumNow. Benefit of continuing combo: protect HACA Ab and longevity of TNFi https://t.co/Q934naKnBq

@RheumNow #acr20 abs0654 we are what we eat: analysis of OmniHeart trial of pts w/HTN reveals DASH-patterns plant-based protein diet can also significantly lower sUA improves HTN &hyperlipidemia. Clincial trial of DASH plant protein based diet in gout would be interesting. https://t.co/5tQwiuwl84

Poll results are in... most chose upadacitinib followed by tofacitinib as their Jak-i of choice if insurance approval was not a factor in those that failed a bDMARD and remain on a cDMARD with high dz activity! @RheumNow @LCalabreseDO @ElaineHusniMD #ACR20 https://t.co/rl1nTqxzKg

• https://twitter.com/meralelramahimd/status/1324768543733407744

Dr Curtis presents SEAM-RA RCT of withdrawal of ETN or MTX in patients on combo therapy in sustained remission. 49.5% of ETN mono retained remission compared to 28.7% of MTX mono, and 52.9% who continued combo therapy. @rheumnow #ACR20 Abstr#939 #ACRbest https://t.co/wpAtBHJYUF

Low pre🤰c3/c4 levels assoc'd w/ ⬆ risk of adverse obstetric outcomes in women w/ aPL w/or w/o APS. Pts w/ triple+ aPL and ⬇ c3/c4 predicts a worse prognosis. @RheumNow #ACR20 https://t.co/Cd2TQBfXSe

@RheumNow #acr20 abs 0649 PROTECT trial of pegloticase in 7 kidney transplant pts w/uncontrolled gout: 2-12 infusions, 2+immunosuppressants on board for transplant care. No change in eGFR, HAQ pain ⬇️by 33.8 at wk20. Alb/cr improved by >35%in 2pts. sUA< 1 mg/dL, no serious AEs https://t.co/f4tnFjMTe8

#myositis & the ❤: lab tests ⬆ Trop = myocardial stress & injury, absence doesn't r/o myocarditis BNP - utility unclear There are no biomarkers specific for myocardial involvement @RheumNow #ACR20 https://t.co/eyihKPoXSc

Does your pt have myocardial inflamm? Trop specific but not sensitive, BNP neither sens or specific. Consider EKG - sensitive (85%), but non-specific- But TTE is essential and cMRI is best! #ACR20 @RheumNow Great lecture from cardiologist, @HopkinsBayview APD https://t.co/6THm37KbQ3

What happens long-term in Kawasaki disease now? Has IVIG availability fixed this? Pop-based cohort, long follow-up. Turns out cardiac event risk, whilst greatest early, continues >10y after - even in those w/o coronary aneurysms @SickKidsNews @McMasterU #ACR20 ABST0937 @RheumNow https://t.co/1T6JmwhXNb

Listen to part I of our #ACR20 Day 1 recap. Listen through the link below or find us on Apple podcasts. https://t.co/W6EMQiF9Rf https://t.co/R1ieCFnIxz

• https://bit.ly/352dlRc

Health plan claims data appears useful to classify inadequate responders in PsA and should be studied further. #ABS0898 #ACR20 @RheumNow https://t.co/jXBr54Fc6Z https://t.co/fAESyo5Uad

• Inadequate Response Among Psoriatic Arthritis Patients Prescribed Advanced Ther…

Gender differences in Axial Spondyloarthritis patients Pooled data from 3 Ixekizumab studies Women: 1⃣older at disease onset (30 vs. 26) 2⃣Longer symptom duration (17.8 yrs vs. 16.7 yrs) 3⃣More peripheral joint pain and lower HLA-B27 @RheumNow #ACR20 Abs#0876 https://t.co/qGHXApi0Ko

@andreafava representing @jhrheumatology @HopkinsBayview at plenary session! Urine proteomic biomarkers can revolutionize the way we see LN, and decrease need for renal Bx #Acr20 @RheumNow Abst#0936 https://t.co/zGoqmBPddT

Can we use urine testing ( and all the cells, proteins, complements, DNA, rna) to predict LN response? Plenary II @SalemAlmaani @BradRovin @RheumNow #ACR20 @OSUWexMed

Great talk #ACR20 Integrating bulk and single-cell RNA-sequencing @Kahlenberglab identifies clinically actionable 5-gene signatures that can effectively differentiate DM from cutaneous lupus lesions. @RheumNow @UMIntMed Also out in @JCI_insight https://t.co/uYS6OJH0Hf https://t.co/KR0wwDb5BK

• JCI Insight - IL18-containing 5-gene signature distinguishes histologically id…